Friday, 9 October 20261:33 pm ISTIndia edition

सच, सीधे आप तक

Book ad space

Just in

India

IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class

Image: Asianet Newsable. Rights remain with the publisher.

Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s efgartigimod.

Read the full report on Asianet Newsable

Story file

Section
India
Topics
Stock market
First reported by
Asianet Newsable
Reporter
stocktwits inc
Published
Friday, 9 October 2026, 12:20 am IST
Coverage
One outlet so far

How this page works. The Headline Update lists this report from Asianet Newsable with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.

Related stories

More India news

See all